Nogo-A inhibition demonstrates potential for spinal cord injury recovery

Post author:
Post published:December 19, 2024
Post category:uncategorized

The latest study results have been published online in the renowned “The Lancet Neurology” journal. A multi-centre clinical trial (NISCI trial: Nogo-A Inhibition in acute Spinal Cord Injury Study) investigated the antibody NG 101 (anti-Nogo-A), which blocks and thus neutralizes the body’s own Nogo-A protein.

Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.

Helpful Links

Subscribe To Us

By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy

UPCOMING EVENTS

You Might Also Like

Novel blood test could predict chronic lung disease in preterm babies within hours of birth

Previously unrecognized class of antibodies can broadly neutralize multiple virus strains

Differing definitions of iron deficiency lead to divergent estimates of prevalence, study finds

Helpful Links

Subscribe To Us